Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects



Status:Recruiting
Conditions:HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:2 - 15
Updated:12/9/2018
Start Date:October 17, 2017
End Date:May 30, 2023
Contact:Shire Contact
Email:ClinicalTransparency@shire.com
Phone:+1 866 842 5335

Use our guide to learn which trials are right for you!

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric Subjects With Primary Immunodeficiency Diseases

The purpose of the study is to acquire additional data on efficacy, safety, tolerability,
immunogenicity, pharmacokinetic (PK) and other parameters of HYQVIA in pediatric (age ≥ 2 to
<16 years) participants with primary immunodeficiency disease (PIDD).


Inclusion Criteria:

1. Participant must have a documented diagnosis of a form of primary immunodeficiency
(PI) involving a defect in antibody formation and requiring gammaglobulin replacement,
as defined according to the International Union of Immunological Societies (IUIS)
Scientific Committee 2015 1 prior to enrollment. The diagnosis must be confirmed by
the sponsor´s Medical Director prior to first treatment with IP in the study.

2. Participant is at least two and below 16 years of age at the time of screening.

3. Participant has been receiving a consistent dose of Immunoglobulin G (IgG),
administered in compliance with the respective product information for a period of at
least three months prior to screening. The average minimum pre-study dose over that
interval was equivalent to 300 mg/kg BW / 4 weeks and a maximum dose equivalent to
1000 mg/kg body weight (BW) / 4 weeks.

4. Participant has a serum trough level of IgG > 5 g/L at screening.

5. If female of childbearing potential, participant presents with a negative pregnancy
test and agrees to employ adequate birth control measures for the duration of the
study.

6. Participant /legally authorized representative is willing and able to comply with the
requirements of the protocol.

Exclusion Criteria:

1. Participant has a known history of or is positive at screening for one or more of the
following: hepatitis B surface antigen (HBsAg), polymerase chain reaction (PCR) for
hepatitis C virus (HCV), PCR for human immunodeficiency virus (HIV) Type 1/2.

2. Abnormal laboratory values at screening meeting any one of the following criteria
(abnormal tests may be repeated once to determine if they are persistent):

1. Persistent alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >
2.5 times the upper limit of normal (ULN) for the testing laboratory

2. Persistent severe neutropenia (defined as an absolute neutrophil count [ANC] ≤
500/mm^3)

3. Participant has anemia that would preclude phlebotomy for laboratory studies,
according to standard practice at the site.

4. Participant has an ongoing history of hypersensitivity or persistent reactions
(urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following
intravenous (IV) immunoglobulin, subcutaneous (SC) immunoglobulin, and/or Immune Serum
Globulin (ISG) infusions.

5. Participant has severe Immunoglobulin A (IgA) deficiency (less than 7.0 mg/dL) with
known anti-IgA antibodies and a history of hypersensitivity.

6. Participant has a known allergy to hyaluronidase.

7. Participant has active infection and is receiving antibiotic therapy for the treatment
of infection at the time of screening.

8. Participant has a bleeding disorder or a platelet count less than 20,000/μL, or who,
in the opinion of the investigator, would be at significant risk of increased bleeding
or bruising as a result of SC therapy.

9. Participant has severe dermatitis that would preclude adequate sites for safe product
administration in the opinion of the investigator.

10. Participant has participated in another clinical study involving an IP or
investigational device within 30 days prior to enrollment or is scheduled to
participate in another clinical study involving an IP or investigational device during
the course of this study.

11. Participant is a family member or employee of the investigator.

12. If female, participant is pregnant or lactating at the time of enrollment.
We found this trial at
19
sites
6565 S. Yale Ave.
Tulsa, Oklahoma 74136
918-392-4550
Principal Investigator: Iftikar Hussain
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
282 Washington St
Hartford, Connecticut 06106
(860) 545-9000
Principal Investigator: Nicholas Bennett
Phone: 860-837-5873
Connecticut Children's Medical Center Connecticut Children’s Medical Center is a nationally recognized, 187-bed not-for-profit children’s...
?
mi
from
Hartford, CT
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
Principal Investigator: Karin Chen
Phone: 801-585-5067
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Albany, Georgia 31707
Principal Investigator: Tracy Bridges
Phone: 229-883-8909
?
mi
from
Albany, GA
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Lisa Kobrynski
Phone: 404-727-5642
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Prescott Atkinson
Phone: 205-934-8347
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Principal Investigator: Rima Rachid
Phone: 617-919-6041
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
Buffalo, New York 14222
Principal Investigator: Heather Lehman
Phone: 716-209-7200
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Charleston, West Virginia 25701
Principal Investigator: Meagan Shepherd
Phone: 304-691-6859
?
mi
from
Charleston, WV
Click here to add this to my saved trials
Charlotte, North Carolina 28277
Principal Investigator: Maeve O'Connor
Phone: 704-910-1402
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28203
Principal Investigator: Niraj Patel
Phone: 704-506-3748
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Dallas, Texas 75230
Principal Investigator: Richard Wasserman
Phone: 972-566-6801
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Fairfax, Virginia 22030
Principal Investigator: Oral Alpen
Phone: 240-643-6002
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
Great Neck, New York 11021
Principal Investigator: Vincent Bonagura
Phone: 516-622-5070
?
mi
from
Great Neck, NY
Click here to add this to my saved trials
Miami, Florida 33166
Principal Investigator: Gary Kleiner
Phone: 305-243-4304
?
mi
from
Miami, FL
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73131
Principal Investigator: Amy Darter
Phone: 405-607-4333
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Megan Cooper
Phone: 314-747-1217
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Saint Petersburg, Florida 33701
Principal Investigator: Jolan Walter
Phone: 727-553-1259
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Stony Brook, New York 11794
Principal Investigator: Susan Schuval
Phone: 631-444-8832
?
mi
from
Stony Brook, NY
Click here to add this to my saved trials